New combo therapy shows promise for tough head and neck cancers
NCT ID NCT03993353
First seen Feb 17, 2026 · Last updated Jun 13, 2026 · Updated 17 times
Summary
This study tested whether adding tadalafil (a drug for erectile dysfunction) to pembrolizumab (an immunotherapy) could help people with advanced head and neck cancer that had come back or spread. Seven adults with measurable disease took part. The main goals were to check safety and see how long they lived after one year. The approach aims to control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCSD Moores Cancer Center
La Jolla, California, 92093, United States
Conditions
Explore the condition pages connected to this study.